Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Statera Biopharma Inc (STAB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.001 0.000    0.00%
06/05 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 13,250
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.001 - 0.001
Statera Biopharma 0.001 0.000 0.00%

Statera Biopharma Inc Company Profile

 
Get an in-depth profile of Statera Biopharma Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

46

Equity Type

ORD

Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers. Its Advanced Immunomodulating Multi-Component System (AIMS) platform is designed to rebalance the body's immune system and restore homeostasis. Its platforms of toll-like receptor (TLR) agonists include R4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. Through its AIMS platform, the Company develops product candidates, which include STAT-200 and STAT-600 AIMS programs. Its STAT-200 program include STAT-201 is focused on treatment of Crohn’s disease. The Company has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205).

Contact Information

Address 4333 Corbett Drive Suite 1082
Fort Collins, 80525
United States
Phone 888 613 8802
Fax -

Top Executives

Name Age Since Title
Michael Kevin Handley 50 2021 CEO, President & Chairman of the Board
Blake Hawley 58 2022 Independent Director
Uday Saxena 65 2022 Independent Director
Satish Chandran 67 2022 Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

STAB Comments

Write your thoughts about Statera Biopharma Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Jonathan McBrine
Jonathan McBrine Dec 09, 2022 11:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what makes you say that target
Duane Goodson
Duane Goodson Jul 11, 2022 3:28PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
STAB Target 5.48
Leroy Smith
Leroy Smith Apr 28, 2022 8:21AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Sundial Growers rises as Q4 results beat forecasts https://seekingalpha.com/news/3828414-sndl-stock-rises-as-company-beats-q4-forecast
Scott Ornelas
Jatslo Oct 19, 2021 2:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
STAB (P) 0.00000000 3.22000000
José Poço
José Poço Sep 07, 2021 11:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🚀
Sohag Rana
Sohag Rana Sep 07, 2021 11:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
💝
José Poço
José Poço Jul 12, 2021 10:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What is happening?? Why is it falling????
José Poço
José Poço Mar 12, 2021 9:44AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🚀
Dec 27, 2020 11:04PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hello~anyone out there?
Mark Jo
Mark Jo Oct 22, 2020 11:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Merger investigation! As if investors needed this. Hope it will get settled fast.
Mark Jo
Mark Jo Oct 20, 2020 3:21PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
4.80 please.
Ryan Swiney
Ryan Swiney Oct 20, 2020 3:21PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
No! You'll get 8.40 and like it & you'll like it!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email